^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
CONTRADICTING EVIDENCE: EGFR EXON 19 DELETION OR L858R MUTATIONS….Progression on erlotinib (± ramucirumab or bevacizumab), afatinib, gefitinib, or dacomitinib….SUBSEQUENT THERAPY...T790M...Osimertinib (category 1) (if not previously given).
Source:
Title:
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
Published date:
09/21/2021
Excerpt:
CONTRADICTING EVIDENCE: UpSwinG was a non-interventional, global, multi-center study (NCT04179890)...in a real-world practice setting who met the following criteria were retrospectively reviewed between November 2019 and July 2020: aged ≥ 18 years with EGFR mutation-positive (Del19 or L858R), TKI-naïve, advanced NSCLC treated with first-line afatinib and, following detection of T790M, second-line osimertinib....The ORR with osimertinib was 45.2% (Table 3); median DoR was 6 months (IQR: 2–10). The DCR was 86.7%. Of 166 evaluable patients, two (1.2%) had a CR, 73 (44.0%) had a PR, 69 (41.6%) had SD and 22 (13.3%) had progressive disease. ORR with osimertinib was consistent across subgroups (Table 3)....This study demonstrated promising activity of...osimertinib in patients with...acquired T790M.
DOI:
https://doi.org/10.1016/j.lungcan.2021.09.009
Trial ID:
Source:
Title:
Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Published date:
02/26/2021
Excerpt:
CONTRADICTING EVIDENCE: Of the 106 patients, 60 (56.6%) had PR, 38 (35.9%) had SD, and 7 (6.6%) had PD. DCR and ORR were 93.4% and 57.5%, including 1 patient with complete remission (CR)....In patients with EGFR exon 19 deletion and exon 21 L858 mutation, the median PFS was 11 (9.2, 12.8) and 12 (9.2, 14.8) months, respectively (p = 0.833)....Osimertinib can effectively treat advanced NSCLC with T790M mutations independently of previous treatment lines.
DOI:
10.2147/CMAR.S287466
Source:
Title:
Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing
Excerpt:
...A 43-year-old smoking man...Genotype by NGS showed EGFR exon19del and EGFR exon20T790M...Osimertinib was initiated and partial response was obtained after 6 weeks. After 5 months, the patient was evaluated with progressive disease with increased liver metastases and new appearance of lung and liver metastases.
DOI:
10.1016/j.jtho.2019.02.014
